Benjamin Brakel

Mr. Benjamin Brakel

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CCChirayu R. Chokshi
Chirayu R. Chokshi
BBBenjamin Brakel
Benjamin Brakel
NTNazanin Tatari
Nazanin Tatari
NSNeil Savage
Neil Savage
SSSabra K. Salim
Sabra K. Salim
Sheila SinghSheila Singh
Sheila Singh
Despite aggressive multimodal therapy, glioblastoma (GBM) remains the most common malignant primary brain tumor in adults. With the advent of therapies that revitalize the anti-tumor immune response, several immunotherapeutic modalities have been developed for treatment of GBM. In this review, we summarize recent clinical and preclinical efforts to evaluate vaccination strategies, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells. Although these modalities have shown long-term tumor regression in subsets of treated patients, the underlying biology that may predict efficacy and inform therapy development is being actively investigated. Common to all therapeutic modalities are fundamental mechanisms of therapy evasion by tumor cells, including immense intratumoral heterogeneity, suppression of the tumor immune microenvironment and low mutational burden. These insights have led efforts to design rational combinatorial therapies that can reignite the anti-tumor immune response, effectively and specifically target tumor cells and reliably decrease tumor burden for GBM patients.

17 December 2024 in International Journal of Stroke
Verified
Journal Article
Open access
BBBenjamin Brakel
Benjamin Brakel
ARAlexander D Rebchuk
Alexander D Rebchuk
JOJohanna Ospel
Johanna Ospel
YCYimin Chen
Yimin Chen
MHManraj Ks Heran
Manraj Ks Heran
TFThalia S Field
Thalia S Field
Background: Cerebral venous thrombosis (CVT) accounts for 0.5–1% of all strokes. The role of endovascular therapy (EVT) in the management of CVT remains controversial and variations in practice patterns are not well known. Aims: Here, we present a comprehensive, international characterization of practice patterns and perspectives on the use of EVT for CVT. Methods: A comprehensive 42-question survey was distributed to stroke clinicians globally from May to October 2023, asking about practice patterns and perspectives on the use of EVT for CVT. Results: The overall response rate was 31% (863 respondents of 2744 invited) across 61 countries. The majority of respondents (74%) supported the use of EVT for CVT in certain clinical situations. Key considerations for decision-making in using EVT favored clinical over radiographic/procedural factors and included worsening level of consciousness (86%) and worsening neurological deficits (76%). In the past 3 years, 56% of respondents used EVT for the treatment of CVT, with most (49.5%) involved in two to five cases. Among interventionalists, significant variability existed in the techniques used for EVT ( p < 0.001), with aspiration thrombectomy (56%) and stent retriever (51%) being the most used overall. Regionally, interventionalists from China predominantly used intra-sinus heparin (56%), while this technique was most commonly ranked as “never indicated” throughout the rest of the world (23%). Post-procedure, low molecular weight heparin was the most used anticoagulant (83%), although North American respondents favored unfractionated heparin (37%), while imaging was primarily split between magnetic resonance (71.8%) and computed tomography (65.9%) arteriography or venography. Conclusion: Our survey reveals significant heterogeneity in approaches to EVT for CVT, and provides a comprehensive characterization of indications, techniques, and long-term management used by clinicians internationally. This resource will aid in optimizing patient selection and endovascular treatments for future trials.

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Programs associated with FEN1 expression in scRNA-seq analysis, related to figure 6B

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Genes associated with FEN1 expression in scRNA-seq analysis, related to figure 6A


5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
A) Normalized intensities of FEN1 protein from immunoblotting related to figure 4A. B) Representative images of comet assays of FEN1i-resistant (BT594) and sensitive (BT972) GSCs exposed to DMSO alone (control), TMZ (200 µM), FEN1i (30 µM) or combination (TMZ/FEN1i, 200 µM/ 30 µM). C) Normalized intensities of phospho-Chek1, total Chek1, phospho-Chek2 and total Chek2 protein from immunoblotting related to figure 4E and 4F. D) Immunoblotting for phospho-ATM, total ATM, phospho-DNAPK and total DNAPK protein normalized to vinculin control.